Search and volunteer to participate in these available studies at UB. Your participation in research doesn't just benefit you, it helps advance healthcare for our entire community.

Highlighted Searches
Search Clinical Trials
Filter on any fields below
?
Compensation may include cash, checks, gift cards, debit cards, or incentives like gift baskets, technology items, or merchandise.
Showing 31 - 40 of 274 Clinical Trials
Description:
A hot work environment can lead to fatigue, hyperthermia, and dehydration, which may increase injury risk and reduce productivity. The goal of this study is to learn more about the body’s response to repeated days of working in a hot and humid environment. Participation will involve 7 visits to the UB South Campus for repeated days of 8-hour periods of sitting or performing moderate-high intensity work in a hot and humid room. Read More
Eligibility:
Males and females ages 18-39
Contact(s)
Riana Pryor
rpryor@buffalo.edu
Description:
The goal of this study is to evaluate the safety, effectiveness and tolerability of a drug compound (AVP- 786) for the treatment of agitation associated with Alzheimer’s Disease. Alzheimer’s Disease causes loss of brain cells and problems with memory, thinking and behavior. Agitated behaviors, such as irritability and restlessness, physical and verbal aggression, and pacing and wandering are major problems in this condition, can be difficult to manage, and can impact your quality of life. AVP-786 is targeted at treating your agitation behaviors. Caregivers are being asked to take part in this research study because the participants may require assistance to complete study procedures and/or attend study visits. Participation in this study will last for approximately 20 weeks and include site visits throughout the study. Read More
Eligibility:
Patients 50 to 90 years of age (inclusive) with clinically significant, moderate-to-severe agitation for at least 2 weeks prior to screening that interferes with daily routine per the Investigator's judgment, and who require pharmacotherapy for the treatment of agitation per the Investigator's judgment after an evaluation of reversible factors and a course of nonpharmacological interventions. A...
Contact(s)
CONNIE BRAND
conniebr@buffalo.edu
+1 716-323-0549
Description:
This study looks at the safety and efficacy of the combination of Pembrolizumab, Carboplatin, & Paciltaxel for patients with incurable head and neck cancer that has returned after being treated or has spread to other body parts. The study will take place at ECMC and can last 2-3 years. Read More
Eligibility:
-Has histologically or cytologically-confirmed diagnosis of recurrent / metastatic head and neck squamous cell carcinoma (HNSCC) that is considered incurable by local therapies.
-Has not had prior systemic therapy administered in the recurrent or metastatic setting. Systemic therapy, which was completed more than 6 months prior to signing consent, if given as part of multimodal treatment f...
Contact(s)
JAMES ZEMER
jameszem@buffalo.edu
+1 716-645-2521
Description:
We are looking for adults ages 18-40 for this study. We are looking for people in general good health and also people who have had a history of blast exposure and blunt head trauma. The purpose of this study is to learn more about balance in people with a history of blast exposure and blunt head trauma compared to healthy people. You will participate in this study for one session that lasts about 3 hours. During the study you will complete balance, vision, and stability tests in our lab. Study visit takes place in the Department of Rehabilitation Science lab at UB's South Campus. Participants will be compensated. Read More
Eligibility:
-Adults ages 18-40.
-Generally healthy OR have had a history of impact brain injury/head trauma in past ten years.
Contact(s)
VIJAYA PRAKASH KRISHNAN MUTHAIAH
vijayapr@buffalo.edu
+1 716-829-5291
Description:
This study enrolls students who participate in the after-school program at a local Buffalo community location. The purpose of this study is to look at reading and literacy skills after a computer based newsletter program. Read More
Eligibility:
-Children ages 10-13.
-Must be in the after-school program at a participating local Buffalo community center in grades 6-8.
-Must have access to a computer: laptop, Chromebook, or desktop with the capability to download Zoom.
-Must have internet access at home or center.
Description:
This study is enrolling patients with pemphigus (vulgaris or foliaceus), a condition where the immune system attacks the skin and/or mucosa (the most superficial layer that lines body cavities and passages, for example, in your mouth). Participants are invited to take place in this study if they are newly diagnosed with pemphigus or have experienced a flareup. The goal of the study is to investigate the safety, effectiveness and tolerability of a drug compound (efgartigimod PH20 SC) in adult patients aged 18 to 80 years with pemphigus. Read More
Eligibility:
Patient has a clinical diagnosis of pemphigus vulgaris or pemphigus foliaceus which has been confirmed by cutaneous histology, positive direct immunofluorescence (IF), and positive indirect IF and/or ELISA.
Contact(s)
CATHERINE WRONA
wrona@buffalo.edu
+1 716-888-4713
Description:
This study enrolls adults with Relapsing Multiple Sclerosis. The purpose of this study is to learn about changes in cognition that happen while being treated with the experimental medication RPC1063 (also known as ozanimod). Read More
Eligibility:
- Adults ages 18-65.
- Have at least 5 years since time of RMS diagnosis.
- Have no clinically relevant cardiovascular conditions.
Contact(s)
KARA PATRICK
kpatrick@buffalo.edu
+1 716-829-5037
Description:
Researchers think the study drug, EPI-7386, may be an effective treatment for metastatic castration-resistant prostate cancer (mCRPC) because the drug works by interfering with the function of the male hormone system that leads to the growth of prostate cancer. Enzalutamide is an androgen receptor inhibitor that works by blocking the action of male hormones (androgens) like testosterone to slow down the growth of prostate cancer. Enzalutamide is approved by the Food & Drug Administration (FDA) and is commonly used as a standard of care option for men with advanced or metastatic castration-resistant prostate cancer. Since EPI-7386 and enzalutamide have not been combined together in humans, we are doing this study to find out whether EPI-7386, in combination with a fixed dose of enzalutamide, compared to standard of care enzalutamide alone, is a safe and effective treatment for men who have mCRPC. Study will be done at Spindrift Clinic location. Read More
Eligibility:
1) Males aged 18 years or older
2) Histologically, pathologically, or cytologically confirmed prostate adenocarcinoma
3) Presence of metastatic disease at study entry
4) Naïve to second generation anti-androgens
Contact(s)
Kyle Pasquariello
kylepasq@buffalo.edu
Description:
We are doing this study to learn more about if the combination of medications (durvalumab, tremelimumab and enfortumab vedotin)before and after bladder removal surgery will work and be safe for the treatment of muscle invasive bladder cancer. Also to better understand the disease and associated health problems. Read More
Eligibility:
1) Participant must be 18 or older years at the time of screening
2) Histologically or cytologically documented muscle-invasive TCC of the bladder with clinical stage of T2-4aN0-N1M0
3) Medically fit for cystectomy and able to receive neoadjuvant therapy
4) Cisplatin-ineligible
Contact(s)
Jessica McCarthy
jm279@buffalo.edu
Description:
The purpose of this study is to learn more about the advantages and disadvantages of two brief quitting smoking approaches that could be cost-effective in assisting individuals who suffer from serious mental illness. The first approach is brief advice combined with the use of nicotine gum and patches. The second approach uses an app on your smartphone combined with the use of nicotine gum and patches. Read More
Eligibility:
Inclusion Criteria
(1) Current DSM-5 diagnosis of schizophrenia, schizoaffective, bipolar, or recurring major depressive disorder;
(2) Functional impairment as indicated by a score of_2 or greater on the WHODAS 8 item version
(3) Smoker as indicated by smoking  5 cigarettes per day over the past 6 months;
(4) Desire to quit smoking as indicated by self-reported serious...
Contact(s)
Constance Duerr
cduerr@buffalo.edu
+1 716-829-6699 ext. 1
Showing 31 - 40 of 274 Clinical Trials
Not finding what you are looking for? Add your profile to the Buffalo Research Registry or ResearchMatch to be matched with future studies.